Switch theme
Sign up to access all valuation multiples
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
1997
7.6K+
LTM Revenue $9.5B
LTM EBITDA $3.2B
$23.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biogen has a last 12-month revenue (LTM) of $9.5B and a last 12-month EBITDA of $3.2B.
In the most recent fiscal year, Biogen achieved revenue of $9.7B and an EBITDA of $2.8B.
Biogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biogen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.5B | XXX | $9.7B | XXX | XXX | XXX |
| Gross Profit | $7.4B | XXX | $7.4B | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $3.2B | XXX | $2.8B | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $2.9B | XXX | $2.2B | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $2.3B | XXX | $1.6B | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biogen's stock price is $130.
Biogen has current market cap of $19.0B, and EV of $23.0B.
See Biogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23.0B | $19.0B | XXX | XXX | XXX | XXX | $15.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biogen has market cap of $19.0B and EV of $23.0B.
Biogen's trades at 2.4x EV/Revenue multiple, and 8.1x EV/EBITDA.
Equity research analysts estimate Biogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biogen has a P/E ratio of 8.2x.
See valuation multiples for Biogen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.0B | XXX | $19.0B | XXX | XXX | XXX |
| EV (current) | $23.0B | XXX | $23.0B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 7.1x | XXX | 8.1x | XXX | XXX | XXX |
| EV/EBIT | 7.9x | XXX | 10.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.2x | XXX | 11.7x | XXX | XXX | XXX |
| EV/FCF | 9.4x | XXX | 9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiogen's last 12 month revenue growth is -3%
Biogen's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.7M for the same period.
Biogen's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biogen's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biogen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -3% | XXX | -3% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biogen acquired XXX companies to date.
Last acquisition by Biogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Biogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biogen founded? | Biogen was founded in 1997. |
| Where is Biogen headquartered? | Biogen is headquartered in United States of America. |
| How many employees does Biogen have? | As of today, Biogen has 7.6K+ employees. |
| Who is the CEO of Biogen? | Biogen's CEO is Mr. Christopher A. Viehbacher. |
| Is Biogen publicy listed? | Yes, Biogen is a public company listed on NAS. |
| What is the stock symbol of Biogen? | Biogen trades under BIIB ticker. |
| When did Biogen go public? | Biogen went public in 1991. |
| Who are competitors of Biogen? | Similar companies to Biogen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Biogen? | Biogen's current market cap is $19.0B |
| What is the current revenue of Biogen? | Biogen's last 12 months revenue is $9.5B. |
| What is the current revenue growth of Biogen? | Biogen revenue growth (NTM/LTM) is -3%. |
| What is the current EV/Revenue multiple of Biogen? | Current revenue multiple of Biogen is 2.4x. |
| Is Biogen profitable? | Yes, Biogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biogen? | Biogen's last 12 months EBITDA is $3.2B. |
| What is Biogen's EBITDA margin? | Biogen's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Biogen? | Current EBITDA multiple of Biogen is 7.1x. |
| What is the current FCF of Biogen? | Biogen's last 12 months FCF is $2.5B. |
| What is Biogen's FCF margin? | Biogen's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Biogen? | Current FCF multiple of Biogen is 9.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
